This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
News|Articles|October 28, 2010
Regulatory Roundup: USP Announces Two Collaborations.
Author(s)Pharmaceutical Technology Editors
The US Pharmacopeia (USP) has announced two new collaborations.
Advertisement
The US Pharmacopeia (USP) has announced two new collaborations. One involves working with the Republican State Enterprise National Center for Expertise of Drugs, Medical Products and Equipment of the Ministry of Health of the Republic of Kazakhstan to share standards for the quality, purity, strength, and identity of medicines. Specifically, the Kazahkhstan center will have a five-year renewable right to include written standards from the USP–National Formulary. Second, USP is joining with six government drug-control laboratories in the Middle East and North Africa to improve their capabilities to test the quality of drugs. Government agencies signing onto the network include: UAE: Health Authority of Abu Dhabi; Egypt: National Organization for Drug Control Research; Jordan: Drug Quality Control Laboratory, Jordan Food and Drug Administration; Morocco: Direction de Médicament Et de la Pharmacie; Saudi Arabia: Products Evaluation and Standards-setting and National Drug and Cosmetic Control Laboratories (NDCCL) in Drug Sector, Saudi Food and Drug Authority; and Tunisia: Laboratoire National de Controle des Medicaments.
Advertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement